<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 369 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page368.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=369">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 369 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 369</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=369"><img src="../thumb/369.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>332 / 2020-04                                  Chelating Agents, Ion Exchange Preparations / Biologicals - 25 / 26
   Do not chew or swallow whole. Do not dispers.in carbonat. drinks,   Special precautions: Monit.electrol.& miner. metabol. Discont.  pon.from manufact., not recomm.in pregn., prev. encephalopathy
   milk not recomm              when serum K is 4-5 mEq./L. Impend.CF, ac./chron.ren.fail.  of unknown origin within 7 days of pertuss.cont. vacc./ other neuro-
   Transfus.Fe overload: . Commenc. ther. aft. transfus.of approx.20   Drug interactions: Toxic eff.of digital.incr.if K bld.lev.low.  logic.complicat.follow.prev. immunisat. with any of above antigens,
   units (equiv.100 ml/kg pack. red bld.cells) or when chron.Fe over-  ac.illn. incl. febrile illn., prim.immunisat./boosters in childr. less than
   load pres. Calc. dos.in mg/kg round.to nearest whole tab. Indiv.   3 yrs., IV/SC inj.
   accord.to anticipat.clinic.benef.& chelat.ther.risks. Dos. recomm.  Side effects: Headache, N&V, diarrh., arthralg./ joint swell., myalg.,
   for paed.pts.same as for adults. When calc.paed.dos.take change  26  BIOLOGICALS  asthen., chills, loc.reacts.incl. inj.site pain/indurat., fatig., fev., sev.upp.
   in weight into account.                                    arm/ extens. limb swell. somet.blister., irritabil., lymphadenopathy,
   Start.dos: Determ.by bld. transfus.freq. Recomm. init.dly.dos: 20 mg/  ERBITUX (MDR Listing)  malaise, pallor, anaphylact. reacts., convuls., vasovag.syncope, Guil-
   kg bw. Init.dly.dos.of 30 mg/kg poss.consid.for pts.rec.more than 14   NEULASTIM (MDR Listing)  lain-Barre syndr., fac.palsy, myelit., brach.neurit., trans. paraesthes./
   ml/kg/mnth of pack.red bld.cells (approx.&gt;4 units/mnth for an adult).   NEUPOGEN (MDR Listing)  hypoaesthes.of vaccin.limb, dizzin.
   Init.dly.dos.of 10 mg/kg poss.consid.for pts. rec.less than 7 ml/kg/  PREVENAR (MDR Listing)  Special precautions: Eval.risk vs.benef.if Guillain-Barre sydr./brach.
                                                                                    st
   mnth of pack.red bld.cells (approx.&lt; 2 units/mnth for an adult). For   ACTEMRA, Roche [P/S]  neurit. prev.exper.aft. vaccinat.with tetan.tox.vacc., 1  treat & stabil.
   pts.well manag. with deferoxamine treatm.consid.an Exjade start.  Tocilizumab  progress./unstab. neurologic.disords./uncontrol. epilep. or progress.
   dos. numeric.half the deferoxamine dos. (eg. deferoxamine 40 mg/  Indications: Mod.to sev.act.rheum.arthrit.in combin. with methotrex-  encephalopathy, poss.not protect all suscept.indiv., immunogenic.re-
   kg/day x5 days/wk. or equiv.could be tfd.to an Exjade start.dly.dos.  ate in adults who have respond. inadeq./intol.to prev.ther.with one or   duc.by immunosuppress.treatm./immunodefic., vaccin. recomm.for
   of 20 mg/kg/day).            more dis. modif.anti-rheum.drugs or tumour necros. factor antagon.,   HIV-infect./chron.immunodefic.indiv., cons.benef.vs risk dur.breast
   Maint: Adjust every 3-6 mnths.base.on trends in serum ferritin. Dos.  as monother.in act.rheum. arthrit. when intol.to methotrex./cont.  feed., not be inj.in glut.area, obt.good prev.medic.hist., caref.consid.
   adjustm.made in steps 5-10 mg /kg tailor.to respon.& ther.goals.   methotrex. ther. inappr., IV also: act.system.juven.idiopath. arthrit. in   vaccinat.if hist of ser./sev.react.within 48 hrs.of prev.inj., do not ad-
   When not adeq. control.with 30 mg/kg dos.of up to 40 mg/kg may be   combin.with methotrexate in pts ≥ 2 yrs. who have respond.inadeq.  min.by intravasc.inj./in fract. dos., approp.med.treatm.& supervis.
   consid. Dos.above 40 mg/kg not recomm.as exper.limit. Consid.dos.  to prev.ther.with NSAIDs & system.corticoster.or as monother.when   to be immed. avail.in case of anaphylact.react., concom. anticoag.
   reduct.in 5-10 mg/kg steps when ser.ferritin lev.reach.target (usually   intol.to methotrex./methotrex.treatm.inappr.  ther., coagulat.disords., 5 yr.interv.betw. Adacel booster.dos.& preced.
   betw. 500-1 000 mcg/L) to maint.ser.lev.within target range. If ser.lev.  (S4) IV INFUS, 43/30.1/0944, 0945, 0946. 20 mg/ml  booster of dipther.& tetan. contain.vacc.to minim.advers.reacts.
   fall consistent.bel.500 mcg/L consid. treatm.interupt.  715813-001: 80 mg/4 ml, 1 vial, R1 169,04  ALBUMIN HUMAN 20 % OCTAPHARMA, Octapharma
   Non-transfus.dependen thalassem.syndr: Only init.ther.in pres.  715814-001: 200 mg/10 ml, 1 vial, R2 922,60  Human albumin 200 g/1000 ml
   of Fe overload (ie ser.ferrit.consist. &gt;800 mcg/L). Start dos: recomm.  715815-001: 400 mg/20 ml, 1 vial, R5 845,19  Indications: Restorat.& maint.of circulat.bld.vol. where vol.defic.
   init.dly dos. 10 mg/kg bw. Dos.adjustm: Monit.ser.ferritin mnthly.   Dosage: See product lit.for prep.& admin.techniq. Admin. by ex-  demonstrat. & use of a colloid appropr.
   Every 3-6 mnths.consid.dos.incr.in 5-10 mg/ kg increm.if ser.ferritin   per.physic.only. Dos.above 1,2 g not eval. Data suggests clinic.  (S4) IV INFUS. 36/30.3/0057
   is consist. &gt;2 000 mcg/L and not show.downward trend & tol. good.   improvem.within 6 wks. Careful.consid.cont.ther.if no improvem.  713087-001: 20%, 50 ml, R357,43
   Dos.above 20 mg/kg not recomm.as no exper. Pts.where ser.ferritin.  within timeframe.  713088-001: 20%, 100 ml, R714,86
   is equal to or less 2 000 mcg/L dos.should not to exceed 10 mg/kg.   Rheumat.arthrit: 8 mg/kg bm once every 4 wks. as IV infus.over 1   Dosage: Admin.IV., warm preparat.to body/room temp.
   Where dos.incr.&gt;10 mg/kg dos.reduct.to 10 mg/kg or less is recomm.  hr. For individ.&gt;100 kg dos. exceed. 800 mg per infus.not recommend.  Conc., dos.& infus.-rate should be adjust.accord.to pt. indiv.requirem.
   when ser.ferritin.is equal or less than 2 000 mcg/L. Once satisfact.   System.juven.idiopath.arthrit: Pts.&lt; 30 kg: 12 mg/ kg bm once   Req.dos.depends on size of pt./ severity of trauma or illness/cont.
   body Fe lev of ser.ferritin.&lt;300 mcg/L achiev.treatm.should be in-  every 2 wks.as an IV infus. Pts.≥ 30 kg: 8 mg/kg bm once every 2   fluid & prot.loss. Meas.adequacy of circulat.vol.& not plasma albu-
   terupt. Re-init.treatm.when chron.Fe overload pres.in clinic.monit.  wks.as an IV infus.  min lev.to determ.the dose reqd. Monit.haemodynam.perform.reg.
   Contraindications: Creatinine clear. &lt;60 mL/ min.), concom.repa-  Dos.adj.due to lab.abnormalit.: Ref.to prod.lit.  Contraindications: Do not mix with other meds./ whole bld. &
   glinide, high risk myelodysplast. syndr., haematologic.& non-hae-  (S4) SC INJ, 49/30.1/0398.   packed red cells., do not dil.with water for inj.
   matologic.malign. with surviv.rate &lt;1 yr.not expect.to benef.due to   723506-001: 162 mg/0,9 ml, 4xprefill.syr, R9 602,27  Side effects: Anaphylact.react./shock, confus. state, headache,
   rapid progress.of their dis., sev.hepat.impairm., pregn.& breast feed.,   Dosage: See prod.lit.for prep.& admin.techniq., treatm. init. by exper.  tachycard., bradycard., hypo-/hypertens., flush., dyspn., naus., urti-
   Side effects: GI disturbs.incl.haemorrh.& ulc., skin rash, elev.liv.  physic.only. Do not shake. Pt. to perform first few injects.und.supervis.  car., angioneurot. oed., erythematos.rash ., incr.sweat., fev., rigors.
   transaminas, hepat.fail.with fatalit.most.with signific.co-morbidit.,   of health. prof., inj.site to be rotat. Assess suitabil.of pt.for SC home   Warnings and special precautions: Discont.& instit. appropr.
   high freq. hear.loss, lenticul.opacit., mild dos.depend.non-progress.   use & instruct pts.to inform a health.prof. if exper.sympts.of allerg.  treatm.if allerg./anaphylact.reacts. occur, observ.curr.medic.stand-
   incr.in ser.creatinine gen.within norm. range, anx., sleep disords.,   react.bef admin.next dos.  ards for treatm.in case of shock, condits.where hyper-volaem.& its
   headache, dizzin., maculopathy, optic neurit., pharyngolaryngeal pain,   Rheumat.arthrit: 162 mg 1x/wk.as SC inj.alone/ in combinat.with   conseq./ haemodilut.could repres.a spec.risk for pt. incl.decompen-
   oesophagit., hepatit., cholelithias., prurit., pigmentat. disords., erythe-  methotrex.&/other DMARDs. Pts. transition. from Actemra IV ther.  sat.card.insuffic./hypertens./ oesophag. varices/pulm.oed./haemorrh.
   ma multiforme, proteinuria., Fanconi’s syndr., pyrex., oed., fatig.,ac.ren.  to SC admin. should admin.1st SC dose at time of next sched.IV dos.   diathes./ sev. anaem./ren.& post-ren.anuria, sev.traumat. brain inj.,
   fail., leukocytoclast.vasculit., urticar., alopec., hypersens.reacts. incl.  und.supervis.of a qualif.health.prof.  adeq.hydrat.when concentrat.albumin is admin.& monit.careful.to
   anaphylax., bld. dyscras., ren.tubulopathy main.in childr.& adolesc.   Missed dose: Ref.to prod.lit.  guard against circulat. overload & hyper-hydrat., monit.electrol.&
   with beta-thalassaem.& ser.ferritin lev. &lt;1 500 mcg/L  Dos.adj.due to lab.abnormalit.: Ref.to prod.lit.  take appropr. steps to restore/maint.electrol.bal., control coagu-
   Warnings and special precautions: Concom. drugs with ulcero-  Contraindications: Act.sev.infects., safety & effic. in pregn.& lactat.  lat.& haematocrit if comparativ.large vol. to be replac.& take care
   gen.potent.& anticoags.incr.GI complicat.risks, most hepat.fail.reports   not est., insuff.data on safety & effic.in childr.bel.2 yrs., concom.use   to ensure adeq. substitut. of other bld.constit.incl.coagulat.facts./
   involv. signif. comorbidit.incl.liv.cirrh & multi-org.fail with some fatal   with other biolog.agents/live vacc.not recomm., SC: safety & effic.  electrol./ platelets & erythrocytes., hyper-volaem. poss.if dos.& rate
   outcomes report., indiv.ther.bas.on anticipat.clinic.benef.& risks, el-  in not demonstrat.in childr., not for IV admin.  of infus.not adjust.to circulat. situat., discont.at first clinic.signs of
   derly, assess.ser. creatinine &/or creatine clear.in duplic.bef.init. ther.   Side effects: Divertic.perforat., ser.hypersens. reacts., URTI, naso-  CV overload or incr.BP/rais.ven.press.& pulm.oed., controll. Na/ K
   & monit.mnthly thereaft., monit.ser. creatinine &/or creatine clear.  pharyngit., hypertens., cellulit., pneum., H.simpl./zost., diverticulit.  diet, reduc.kidn.funct., infect.dis.due to transmiss. of infect.agents
       st
   wkly.in 1  mnth.aft. init./ ther.modificat.& mnthly thereaft.in pts.  complic., GI disords. incl.peritonit./fistul., skin/inj.site reacts., periph.   cannot be total.excl., use in pregn.& lactat.not est.although clinic.
   with pre-exist.ren.condit./concom.ren.depress.ther., ren. tubulopathy   oed., headache, dizzin., bld.dyscras., abnorm. hepat. funct., conjunc-  exper.sugg.no harmful eff.expect.
   report.predomin.in childr.& adolesc. with beta-thalassaem.& ser.fer-  tivit., ser.infects. incl. sepsis/bact.arthrit., opportunist.infects., lipid
   rit.lev. &lt;1 500 mcg/L, adeq.hydrat.in diarrh.& vomit., reduc. dly.dos.in   paramet. elev., decr.platel./neutroph.count with methotrex., neph-  ALBUSOL 4%, 20%, NBI
   adults by 10 mg/kg unexplain. non-progress.rise by 33% above aveg.  rolithias., hypothyroid. pancytopen.  Human plasma albumin deriv.from pool.human plasma, steril., pas-
   pre-treatm. measurem.at 2 consec.visits, reduc.paed.dos.by 10 mg/  Warnings and special precautions: Monother. effic. not been   teur., test.& found non-react.to HBsAg & antibodies to HCV, HIV-1
   kg if ser.creatin.lev.rise above age-appropr. ULN at 2 consecut.visits.,   demonst.for more than 6 mnths., treatm. to be interrrupt.until contr.if   & HIV-2 virus.
   if ser creatin.incr. progress. above ULN interrupt.ther.which may be   pts.devel.ser. infect., recurr./chron.infect.hist./underly.condits. which   Indications: Hypovolaem.shock assoc.with bld loss, trauma & surg.,
   re-init.depend.on indiv.clinic.circumst., monit.liv. funct.bef.init.ther./2   may predisp.to infect., pts.receiv.biolog. treatm. for mod./sev.RA,   sev.burns (&gt; 15% body surf. area) aft.24 hrs.if hypoproteinaem.devel-
   wkly.dur.1 mnth.& mnthly thereaft.& interrupt.ther.if unexplain.per-  report S & S of infect. immed., monit.for latent TB, anti-mycobact.  ops/ to maint. plasma vol., in conjunct.with diuret.to promot. diures.
       st
   sist.& progress.ser.transaminas.lev.report., monit.for S&S of GI ulcer-  treatm. bef. init.ther.in case of latent TB, intestin.ulcerat./ diverticu-  in hypoproteinaem.caus.by plasma prot. loss, maint.CV funct.follow.
   at.& haemorrh., poss.interrupt.of treatm.necess.for sev.skin rash.but   lit. hist., appropr.treatm.to be avail.in case of anaphylax., no exper.  drain.large vol.of ascit. fluid. Albusol 20% only: As adjunct.in long-
   may be re-introduc. aft.rash resolut.at low.dos.follow.by grad. dos.   with TNF antagon.use, incr. spontan.abort./embryo-foet.death risk   term dialys.pts.suscept.to shock & hypotens./ dialys. pts.who are
   escalat., audit.& opthalm.test.recomm.bef. treatm. & at reg.12 mnthly   at high dos. in animals, norm.immune respons.poss.aff., act. hepat.  hypovolaem.& intoler.of large vol. of crystalloid infus.
   interv., discont.if unexplain. cytopaen.develops & consid.reintroduct.   dis./impairm., monit. AST/ALT lev.4-8  wkly. for 1  6 mnths.then   (S4) IV INFUS. T/30.3/738, 739.
                                                      st
   once cytopen.cause elucidat., toxic.risks incr.with inapprop.high dos.to   12 wkly.theraft., low neutroph./ platel.count, lipid.paramet./neutroph   802840-019: 4%, 8 g/200 ml, 200 ml, R458,50
   pts.with low Fe burden or only slightly elev.ser.ferrit.lev., monit.bm.&   & platelet count to be monit.4-8 wks.aft.init.ther., incr. malign.incid.  802867-006: 20%, 10 g/50 ml, 50 ml, R384,45
   longitudin. growth in paeds.at 12 mnthly.interv., do not combine with   under ongoing eval., incr.CV dis. disords. risk, treatm.not recom.where   802859-003: 20%, 20 g/100 ml, 100 ml, R768,90
   other Fe chelat.ther.as safety not est., lact.intol., do not admin.with   baseline AST or ALT &gt;5xULN, sympt.potent.indicat.of new-onset   Dosage: Admin.IV. at rate of about 1 ml/min. Infus. rate & tot.vol.to
   concom. Al-contain. antacid.preps., monit.concom.theophyll. conc.,   centr. demyelinat.disords., low sod.diets, incr. neutropen. risk in pts.  be infused depend.on indicat. & haemodynam.respons. Whole bld./
   reproduct.toxic.& extens.excret.in matern. milk in animals.  prev.treat.with TNF antagon., no studies in liv./ren.dis., all pts.partic.   pack. cells transfus.may be neccess.aft.admin.of large vol. of albu-
   Drug interactions: GI complicat.risk incr.with known ulcerogen.po-  sJIA pts.to be up to date with immunisat.as per curr. guidelines, not   min 20 %. Dos.guidelines:
   tent.drugs & anticoags., decr. effic.of subst.metabol.through CYP3A4,   studied dur.act.macrophage activat. syndr.episode, viral reactivat.   Hypovolaem. & ascites: Adults: Init.dos: Approx. 25 g as IV infus.
   expos. decr. by potent UDP-glucuronosyltransferase induc., AUC &   SC: Pts. should seek immed.medic.attent.if ser.allerg. reacts develop.  If clinic.respons.not achiev. within 15-30 mins., addit.dos.may be giv.
   Cmax.of repaglinide (a CYP2C8 substrate) incr.theref.interact.with   Drug interactions: CYP450 poss.reversed, meds. metabol.via   Paed.dos: Init.approx.2,5-12,5 g in tot.or 0,5-1 g/ kg bm as IV infus.
   other CYP2C8 substrates cannot be excl., AUC of theophylline (a   CYP450 1A2/2C9/2C19 & CYP3A4 poss. need incr.dos.  If adeq.respons.not achiev. within 15-30 mins., addit.dos.may be giv.
   CYP1A2 substrate) incr. theref.interact.with other CYP1A2 substrates   Burns: Adults & paed.dos: Recomm.ther.start with admin.of large
   poss.,incr.bioavail.when taken with food., vit.C dos.of 200 mg/day as-  ADACEL QUADRA, Sanofi-Aventis [P/S]  vol.of crystalloid infus.to maint. plasma vol. Albumin may be add.
   soc.with advers. conseq.     Diphtheria toxoid 2 Lf, tetanus toxoid 5 Lf, pertuss.toxoid(PT) 2,5 µg,   aft.24 hrs. at init.dos.of 25 g, adjust dos.theraft.
                                filamentous haemagglutinin(FHA) 5 µg, fimbriae types 2+3 (FIM) 5 µg,   Hypoproteinaem: Adults: 50-75 g admin.IV
   KEXELATE, Al Crit.Care [P/S]  pertactin (PRN) 3 µg, poliovirus.type 1 40 D-Antigen units, poliovirus.  Plasma exchange/dialys: 20% sol.only: Adults: Admin.25 g
   Na-polystyrene sulphonate with cation-exchange capac. of approx.   type 2 8 D-Antigen units, poliovirus.type 3 32 D-Antigen units/ 0,5 ml.  as IV infus.with rate not exceed.30 ml/ min.dur.plasma exchange.
   3,1 mEq of K/g. Na content approx. 100 mg/g.  Indications: Activ.immunisat.against diphtheria, tetanus, pertus-  Contraindications: Where hypervolaem./ haemodilut. represents
   Indications: Hyperkalaem.assoc.with oligur./ anur.due to ac.tubular necros.  sis & poliomyelit. in persons aged 3 to 64 yrs as a booster dos.fol-  spec.risk, safety in pregn. not est.
   (S0) POWD. H1748.            low.prim.vaccinat.            Side effects: N&V, incr.salivat., febr.reacts., chills, flush., urticar.,
   734985-003: 454 g, R1 334,83  (S2) INJ. 42/30.1/0118       fev., pulm.oed.
   Dosage: Aveg.adult dos: 15 g orally mix.with 20-100 ml fluid 1-4xdly   713229-001: sngl.dos.pre-fill.syr., R311,64  Special precautions: In burns & sev.shock.pts. defer admin.till
   or as enema 30 g 1-2xdly in 150-200 ml warm aqueo.veh., retain for   Dosage: Shake well bef.use. Admin.as sngl.inj.of 1 dos. = 0,5 ml.   phase of maxim.capill.permeabil. to albumin molecul.is over ie.first
   4-10 hrs, then follow by cleans.enema.  Admin.IM pref.into deltoid musc.  24 hrs., discont. immed. in case of ac.allerg.shock, card.insuffic. pts.,
   Side-effects: Anorex., N&V, GI-irrit., diarrh./ faecal impact., K-  Contraindications: Treatm.of dis.caus.by B.pertussis/ C   monit.coagulat.& haematocrit if large vols. replac., serum gluc.monit.
   defic., oed., hypertens.     diptheriae/C tetani or poliomyelit. infect., hypersens.to resid.com-  in diab.when using 4% sol., reg.bld.monitor.to ensure substitut.of</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page368.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>
             </td>
             <td width="35%"><a href="page370.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page370.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
